Last reviewed · How we verify
PIEMONTE
Piemonte's mechanism of action is not publicly available.
At a glance
| Generic name | PIEMONTE |
|---|---|
| Sponsor | EMS |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Due to limited information, a detailed explanation of Piemonte's mechanism cannot be provided.
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus (PHASE3)
- Non-inferiority RCT on Fish Waste-Derived vs. Synthetic Vitamin D Supplementation in Healthy Adults With Suboptimal Vitamin D Levels (NA)
- Active Surveillance or Radical Treatment for Newly Diagnosed Patients With a Localized, Low Risk, Prostate Cancer START
- Effectiveness of a Cognitive and Physical Intervention to Reduce Head and Muscle Pain in a Large Population (PHASE3)
- 5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |